Benralizumab (Fasenra®)

Covered: Fasenra (benralizumab) is approved as add‑on maintenance therapy for patients ≥12 years with severe eosinophilic asthma (initial approval 6 months, renewals 12 months) when specified criteria are met. Key requirements: blood eosinophils ≥150 cells/µL within 6 weeks, ≥3 months of prior controller therapy (ICS + anti‑IL‑5 or ICS + another controller or an ICS/LABA), evidence of uncontrolled asthma (exacerbation or spirometry criteria or steroid‑dependent worsening), prescribed by or in consultation with an allergist/immunologist/pulmonologist, and for reauthorization ≥6 months of Fasenra, continued ICS use and documented clinical response.

"Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype."

Sign up to see full coverage criteria, indications, and limitations.